Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer
Authors
Keywords
-
Journal
BIOORGANIC CHEMISTRY
Volume 140, Issue -, Pages 106833
Publisher
Elsevier BV
Online
2023-09-05
DOI
10.1016/j.bioorg.2023.106833
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of bromodomain and extraterminal (BET) proteins in prostate cancer
- (2023) Adel Mandl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Recent progress and structural analyses of domain‐selective BET inhibitors
- (2023) Anand Divakaran et al. MEDICINAL RESEARCH REVIEWS
- BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
- (2023) Kenneth K. W. To et al. MOLECULES
- Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
- (2022) Yutuan Wu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
- (2022) Xiaofei Zhang et al. Aging-US
- BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
- (2021) Jiawei Guo et al. JOURNAL OF CLINICAL INVESTIGATION
- Current status in the discovery of dual BET/HDAC inhibitors
- (2021) Qinghua Ren et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
- (2021) Pan Tang et al. JOURNAL OF MEDICINAL CHEMISTRY
- A common binding motif in the ET domain of BRD3 forms polymorphic structural interfaces with host and viral proteins
- (2021) Sriram Aiyer et al. STRUCTURE
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Skin adnexal carcinoma with BRD3‐NUTM2B fusion
- (2021) Belen Rubio Gonzalez et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Functional Roles of Bromodomain Proteins in Cancer
- (2021) Samuel P. Boyson et al. Cancers
- BET Proteins as Attractive Targets for Cancer Therapeutics
- (2021) Joanna Sarnik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
- (2021) Lu Feng et al. MEDICINAL RESEARCH REVIEWS
- Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor
- (2021) Andrew D. Woods et al. PEDIATRIC BLOOD & CANCER
- Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
- (2021) Ufuk Erdogdu et al. NEOPLASIA
- Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
- (2020) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
- (2020) Tina Bagratuni et al. EUROPEAN JOURNAL OF CANCER
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation
- (2020) Alessandra Colamatteo et al. Frontiers in Immunology
- The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells
- (2020) Stephanie Laszig et al. CANCER LETTERS
- Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
- (2020) Dailin Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells
- (2020) Zhaoping Pan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
- (2020) George S. Sheppard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
- (2020) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel dual BET and PLK1 inhibitor WNY0824 exerts potent anti-tumor effects in CRPC by inhibiting transcription factor function and inducing mitotic abnormality
- (2020) Ying Xu et al. MOLECULAR CANCER THERAPEUTICS
- Opposing Functions of BRD4 Isoforms in Breast Cancer
- (2020) Shwu-Yuan Wu et al. MOLECULAR CELL
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
- (2020) Jennifer Y. Ge et al. Nature Communications
- BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
- (2020) Siqi Zhou et al. Oncogenesis
- Role of BET Inhibitors in Triple Negative Breast Cancers
- (2020) Durga Khandekar et al. Cancers
- Targeting epigenetic reader domains by chemical biology
- (2020) Alessandra Cipriano et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Domain-selective targeting of BET proteins in cancer and immunological diseases
- (2020) Massimo Petretich et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Characterization of a dual BET / HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
- (2020) Xin Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases
- (2020) Kaikai Lv et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Design and Synthesis of a Highly Selective and In Vivo Capable Inhibitor of the Second Bromodomain (BD2) of the Bromodomain and Extra Terminal Domain (BET) Family of Proteins
- (2020) Alex Preston et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
- (2020) Xiaosa Chang et al. Acta Pharmaceutica Sinica B
- The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
- (2020) Ana S. Leal et al. Cancers
- Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
- (2019) Ellen Watts et al. JOURNAL OF MEDICINAL CHEMISTRY
- First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
- (2019) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Emerging roles of and therapeutic strategies targeting BRD4 in cancer
- (2019) Mary E. White et al. CELLULAR IMMUNOLOGY
- Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail
- (2019) Linlin Lu et al. CELL DEATH AND DIFFERENTIATION
- Role of Brd4 in the production of inflammatory cytokines in mouse macrophages treated with titanium particles
- (2019) Yuanzhong Ren et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV
- (2019) Qingli Niu et al. JOURNAL OF CLINICAL INVESTIGATION
- Bromodomains: a new target class for drug development
- (2019) Andrea G. Cochran et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
- (2019) Deheng Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bromodomain biology and drug discovery
- (2019) Nilesh Zaware et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4
- (2019) Yoel Rodríguez et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system
- (2019) Michael T. Werner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis
- (2019) Fei Jiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment
- (2019) Ekaterina Kim et al. LEUKEMIA
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators
- (2018) Dorothy C. C. Wai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain
- (2018) Robert P. Law et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
- (2018) Sara Bolin et al. ONCOGENE
- Targeting bromodomain and extraterminal proteins in breast cancer
- (2018) Jennifer M. Sahni et al. PHARMACOLOGICAL RESEARCH
- Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
- (2018) A. C. Runcie et al. Chemical Science
- Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
- (2018) Karin Bauer et al. Oncotarget
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
- (2018) Shuai Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- 411OInitial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer
- (2018) J Hilton et al. ANNALS OF ONCOLOGY
- PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
- (2018) Yuan Ren et al. JOURNAL OF CLINICAL INVESTIGATION
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
- (2018) Jean-Philippe Lambert et al. MOLECULAR CELL
- Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents
- (2018) Gaoliang Cheng et al. BIOORGANIC CHEMISTRY
- BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations
- (2017) Mark C. Markowski et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Epigenetic Strategies to Boost Cancer Immunotherapies
- (2017) Maria Barrero INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
- (2017) S Peirs et al. LEUKEMIA
- Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation
- (2017) Ka Lung Cheung et al. MOLECULAR CELL
- RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN
- (2017) Valentina Sancisi et al. NUCLEIC ACIDS RESEARCH
- Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition
- (2017) K A Gelato et al. ONCOGENE
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis
- (2017) Ji-Eun Lee et al. Nature Communications
- Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer
- (2017) Jung-Eun Jang et al. Cell Reports
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors
- (2016) Zhimin Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic Neoplasms
- (2016) Maria Kleppe et al. CANCER CELL
- A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm
- (2016) Michele Ceribelli et al. CANCER CELL
- Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers
- (2016) Peter J. O’Dwyer et al. CANCER RESEARCH
- Molecular Pathways: Targeting the PI3K Pathway in Cancer--BET Inhibitors to the Rescue
- (2016) E. E. Stratikopoulos et al. CLINICAL CANCER RESEARCH
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Combination of the novel BET inhibitor BI 894999 with CDK9 inhibition suggests a promising regimen for the treatment of AML
- (2016) U. Tontsch-Grunt et al. EUROPEAN JOURNAL OF CANCER
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- (2016) Mark L. McCleland et al. JOURNAL OF CLINICAL INVESTIGATION
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells
- (2016) S V Muralidharan et al. ONCOGENE
- Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
- (2016) Olaf Klingbeil et al. Cell Death & Disease
- BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
- (2016) N. Tasdemir et al. Cancer Discovery
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
- (2016) Yue Zhao et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Discovery of Chemical Inhibitors of Human Bromodomains
- (2015) Guangtao Zhang et al. CHEMICAL REVIEWS
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- BET Protein BRDT Complexes With HDAC1, PRMT5, and TRIM28 and Functions in Transcriptional Repression During Spermatogenesis
- (2015) Li Wang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
- (2015) Lei-lei Fu et al. Oncotarget
- Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- (2015) Gabor Borbely et al. Oncotarget
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
- (2015) Marie Loosveld et al. Oncotarget
- INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
- (2015) Jun Li et al. NEOPLASIA
- BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos
- (2014) W Liu et al. CELL DEATH AND DIFFERENTIATION
- Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
- (2014) Mar Gacias et al. CHEMISTRY & BIOLOGY
- Small Molecule Control of Chromatin Remodeling
- (2014) Aidan Finley et al. CHEMISTRY & BIOLOGY
- Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
- (2014) S. E. Trabucco et al. CLINICAL CANCER RESEARCH
- BET bromodomain proteins are required for glioblastoma cell proliferation
- (2014) Chiara Pastori et al. Epigenetics
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
- (2014) Jun Long et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
- (2014) Marie Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Abstract C244: Development of the BET bromodomain inhibitor OTX015.
- (2014) J. K. Noel et al. MOLECULAR CANCER THERAPEUTICS
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
- (2014) Tomohiko Kanno et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
- (2014) Maria Giuseppina Baratta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
- (2014) M. G. J. Baud et al. SCIENCE
- The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
- (2014) Stephen J. Atkinson et al. MedChemComm
- The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
- (2014) C Wong et al. Cell Death & Disease
- Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes
- (2014) Raffaella Di Micco et al. Cell Reports
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
- (2013) S. Picaud et al. CANCER RESEARCH
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- BET bromodomain inhibitors: a patent review
- (2013) Jean-Marc Garnier et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
- (2013) Guangtao Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
- (2013) M A Dawson et al. LEUKEMIA
- BRD4 Coordinates Recruitment of Pause Release Factor P-TEFb and the Pausing Complex NELF/DSIF To Regulate Transcription Elongation of Interferon-Stimulated Genes
- (2013) M. C. Patel et al. MOLECULAR AND CELLULAR BIOLOGY
- The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing
- (2013) Jarmila Hnilicová et al. MOLECULAR BIOLOGY OF THE CELL
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
- (2013) Z Zou et al. ONCOGENE
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
- (2013) Anastasia Wyce et al. PLoS One
- Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)
- (2012) Jonathan Seal et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Bromodomain-dependent stage-specific male genome programming by Brdt
- (2012) Jonathan Gaucher et al. EMBO JOURNAL
- The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets
- (2012) F. de Paula Careta et al. HAEMATOLOGICA
- Cyclin-dependent kinase inhibitors move into Phase III
- (2012) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Bromodomains as therapeutic targets
- (2011) Susanne Muller et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network
- (2010) Liming Zhang et al. CARCINOGENESIS
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Control of Inducible Gene Expression by Signal-Dependent Transcriptional Elongation
- (2009) Diana C. Hargreaves et al. CELL
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
- (2009) Anup Dey et al. MOLECULAR BIOLOGY OF THE CELL
- Cooperative binding of two acetylation marks on a histone tail by a single bromodomain
- (2009) Jeanne Morinière et al. NATURE
- The Bromodomain Protein Brd4 Stimulates G1Gene Transcription and Promotes Progression to S Phase
- (2008) Kazuki Mochizuki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
- (2008) Gary LeRoy et al. MOLECULAR CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started